Keyword: AbbVie

Boehringer just won a skirmish in its high-stakes battle over Humira’s patents, gaining access to documents AbbVie had fought to keep secret.

Sen. Charles Grassley, R-Iowa, vowed to haul pharma CEOs into Senate drug-pricing hearings. Now, several have heeded the call.

Gilead Sciences launches its first campaign for hepatitis C treatment Epclusa, highlighting its versatility across different strains of the disease.

Add another indication for Imbruvica in chronic lymphocytic leukemia to the list.

Washington plans to treat tens of thousands of hepatitis C patients on state-purchased health insurance.

Humira was only a couple million dollars away from its $20 billion sales goal for 2018, but 2019 will be worse, say AbbVie executives.

The European exodus from branded Humira to biosimilars confirms that AbbVie was was way too optimistic about sales erosion, a Bernstein report reveals.

AbbVie’s first campaign for Orilissa is a play on the brand name for the endometriosis pain drug.

AbbVie and Johnson & Johnson’s blockbuster Imbruvica is approved to treat six diseases, but it looks like pancreatic cancer won’t be its seventh.

With Bristol kicking off 2019 at the dealmaking table, will other companies follow suit? Drugmakers such as AbbVie, Gilead have the need—and the funds.